Jazz Pharmaceuticals plc (JAZZ)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Jazz Pharmaceuticals plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Jazz Pharmaceuticals plc (JAZZ) has returned 11.21% so far this year and 52.28% over the past 12 months. Over the last ten years, JAZZ has returned 3.52% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jun 1, 2007, JAZZ's average daily return is +0.14%, while the average monthly return is +2.66%. At this rate, your investment would double in approximately 2.2 years.

Historically, 52% of months were positive and 48% were negative. The best month was Jun 2009 with a return of +270.0%, while the worst month was Jan 2009 at -50.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.

On a daily basis, JAZZ closed higher 50% of trading days. The best single day was Jun 10, 2009 with a return of +209.8%, while the worst single day was Nov 12, 2008 at -40.2%.

Jazz Pharmaceuticals plc has an annualized alpha of 26.79%, beta of 1.12, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since June 04, 2007.

• This stock captured 155.07% of S&P 500 Index gains and 123.32% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

JAZZ ranks 79 for risk / return — better than 79% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Jazz Pharmaceuticals plc (JAZZ) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Jazz Pharmaceuticals plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Jazz Pharmaceuticals plc was 96.90%, occurring on Apr 23, 2009. Recovery took 408 trading sessions.

The current Jazz Pharmaceuticals plc drawdown is 3.95%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Jazz Pharmaceuticals plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Jazz Pharmaceuticals plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.